<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700841</url>
  </required_header>
  <id_info>
    <org_study_id>669-19</org_study_id>
    <secondary_id>NCI-2015-00743</secondary_id>
    <nct_id>NCT02700841</nct_id>
  </id_info>
  <brief_title>Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation</brief_title>
  <official_title>A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution&#xD;
      following transplantation of an autologous mobilized graft product to reconstitution&#xD;
      following transplantation of a mobilized graft product followed by an autologous lymphocyte&#xD;
      infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines&#xD;
      pre and post-transplant. The primary end point will be tetanus vaccine immune responses&#xD;
      post-transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
        1. To compare the cellular and humoral vaccine response post-transplant between the two&#xD;
           arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays&#xD;
&#xD;
        2. To determine the feasibility and safety of this approach&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        1. To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19,&#xD;
           NK, γδ T-cells), in addition to T-cell phenotype markers between the two arms.&#xD;
&#xD;
        2. To compare post-transplant recovery of T-regs and MDSCs between the two arms.&#xD;
&#xD;
        3. To compare progression free survival (PFS) at 2 years post-transplant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of safely treated patients (feasibility and safety)</measure>
    <time_frame>Baseline to 180 days post-transplant</time_frame>
    <description>Determine safety of outcomes by CTCAE version 5.0 tool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Kaplan Meier method, Logrank test, and Cox model will be employed to investigate the effect of ALC, AMC, and immune cells on survival post AHSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation--CD34 HSCT</intervention_name>
    <description>Undergo autologous CD34 HSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <other_name>PBPC Transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation--AHSCT</intervention_name>
    <description>Undergo AHSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous CD34 HSCT</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus Toxoid Vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (vaccine, CD34 transplant, DLI)</arm_group_label>
    <arm_group_label>Arm II (vaccine, stem cell transplant)</arm_group_label>
    <other_name>Tetanus Toxoid</other_name>
    <other_name>TT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 19 years to 70 years old at time of study entry (consent)&#xD;
&#xD;
          2. Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group&#xD;
             (IMWG) criteria .&#xD;
&#xD;
          3. Must have measurable disease defined as: for secretory MM, serum monoclonal protein&#xD;
             ≥1.0 g/dL, urine monoclonal protein ≥200 mg/24 hrs, and involved free light chain ≥ 10&#xD;
             mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage ≥30%.&#xD;
&#xD;
          4. Must have standard risk myeloma (see exclusion criterion 4).&#xD;
&#xD;
          5. Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of&#xD;
             induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may&#xD;
             be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary&#xD;
             clinically for cytoreduction)&#xD;
&#xD;
          6. Able to understand and sign a consent form.&#xD;
&#xD;
          7. Creatinine clearance equal or &gt; 60 ml/min (calculated)&#xD;
&#xD;
          8. Ejection fraction equal or &gt; 50% before admission for transplant as per institutional&#xD;
             standards. Patients with coronary heart disease (recent myocardial infarctions,&#xD;
             angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to&#xD;
             be cleared by cardiology as per institutional BMT standards.&#xD;
&#xD;
          9. Serum bilirubin, ALT, AST less than 3 X upper limit of normal&#xD;
&#xD;
         10. FVC, FEV1 or DLCO &gt;50% predicted before admission for transplant as per institutional&#xD;
             standards. Patients on home oxygen are not allowed on the protocol.&#xD;
&#xD;
         11. No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of&#xD;
             the start of the induction therapy).&#xD;
&#xD;
         12. KPS ≥ 70%or ECOG 0-2.&#xD;
&#xD;
         13. Must be eligible to receive Melphalan dose of 200mg/m2&#xD;
&#xD;
         14. A female of child-bearing potential, must have two negative urine pregnancy test&#xD;
             results within 10 to 14 days prior to starting the first dose of vaccine&#xD;
             pre-transplant as a way of ensuring safe transplant planning.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical study with an investigational product during the&#xD;
             last 28 days.&#xD;
&#xD;
          2. Prior stem cell transplant (either autologous or allogeneic)&#xD;
&#xD;
          3. Creatinine clearance &lt; 60 ml/min (calculated)&#xD;
&#xD;
          4. High risk MM defined as those with the following disease, fluorescence in situ&#xD;
             hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14),&#xD;
             t(14;16), t(14;20), &gt;1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell&#xD;
             leukemia (primary or secondary), or subjects who failed to achieve ≥PR to induction&#xD;
             therapy (i.e. VRd) and required salvage induction prior to AHSCT.&#xD;
&#xD;
          5. Documented central nervous system or extramedullary disease.&#xD;
&#xD;
          6. Significant organ dysfunction deemed to carry inappropriate risk for AHSCT.&#xD;
&#xD;
          7. Intention or plans for cyclophosphamide mobilization.&#xD;
&#xD;
          8. Known allergic reactions after previous tetanus diphtheria vaccination or had a&#xD;
             condition of Guillain Barre Syndrome (GBS)&#xD;
&#xD;
          9. Known active hepatitis B, C or HIV infections on initial assessment.&#xD;
&#xD;
         10. Enrollment on any other transplant related protocols.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhamed Baljevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhamed Baljevic, MD</last_name>
    <phone>402-559-8562</phone>
    <email>muhamed.baljevic@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amberley Proctor, RN</last_name>
    <phone>402-836-9171</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amberley Nurse Coordinator</last_name>
      <phone>402-836-9171</phone>
    </contact>
    <contact_backup>
      <last_name>Christian Project Coordinator</last_name>
      <phone>4025595524</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Christopher Dangelo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

